CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

SARS-CoV-2 plasmaWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2625 Values Clarification and Attitudes Transformation (VCAT) Workshop Wiki 1.00

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D045169 Severe Acute Respiratory Syndrome NIH 0.05
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Convalescent Plasma to Treat Coronavirus - Associated Severe Pulmonary Complications: A Feasibility Study Assessing the Safety of Multiple Doses of Anti-SARS-CoV-2 Plasma in Patients With Severe Respiratory Distress Due to COVID-19

Beyond supportive care, there are currently no proven therapeutic options for pneumonia due to coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and will be available when sufficient numbers of people have recovered. Such persons should have high titer neutralizing immunoglobulin-containing plasma.

NCT04411602 Severe Acute Respiratory Syndrome COVID Drug: SARS-CoV-2 plasma
MeSH:Severe Acute Respiratory Syndrome Coronavirus Infections

Primary Outcomes

Description: Identification of patient population in ICU that are in acute respiratory failure due to COVID-19 and transfuse with convalescent plasma

Measure: Transfusion of patients in the ICU with convalescent plasma for COVID-19-induced respiratory failure.

Time: Track patient progress for 28 days post initial convalescent dose.

Secondary Outcomes

Description: Measure reduction in ventilator use and/or changes in mechanical ventilator parameters

Measure: Ventilatory free days

Time: Track patient progress for 28 days post initial convalescent dose.

Description: Measure length of stay from the time of admission to the hospital and subsequent admission to the ICU. Document resolution of COVID-19 infection or alternatively patient death.

Measure: Patient mortality (including death from any cause)

Time: Track patient progress for 28 days post initial convalescent dose.

No related HPO nodes (Using clinical trials)